Valuation: Sanofi

Market Cap 84.84B 1,723B 95.1B 79.04B 71.93B 135B 9,158B 136B 955B 372B 4,674B 357B 349B 15,025B P/E 2026 *
11.3x
P/E 2027 * 9.81x
Enterprise Value 96.74B 1,965B 108B 90.13B 82.02B 154B 10,444B 156B 1,089B 424B 5,330B 407B 398B 17,134B EV / Sales 2026 *
2.03x
EV / Sales 2027 * 1.85x
Free-Float
88.34%
Yield 2026 *
6.01%
Yield 2027 * 6.35%
1 day+3.14%
3 months+3.14%
6 months-11.80%
Current year-11.80%
Current year 1,486.08
Extreme 1486.08
1,532.71
1 year 1,486.08
Extreme 1486.08
1,737.7
3 years 1,486.08
Extreme 1486.08
2,153.45
5 years 1,486.08
Extreme 1486.08
2,167.9
10 years 1,486.08
Extreme 1486.08
2,167.9
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer - 01/09/2026
Director TitleAgeSince
Director/Board Member 61 30/04/2019
Director/Board Member 56 28/04/2020
Director/Board Member 65 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+3.14%-.--% - - 95.48B
+0.58%-2.77%+36.32%+112.75% 1,019B
-1.08%-6.69%+34.86%+61.48% 617B
+0.27%-1.09%+14.42%+78.63% 464B
-2.96%-5.72%+57.87%+35.32% 356B
+0.93%-1.83%+20.98%+41.43% 333B
+0.12%-4.05%+10.09%+33.53% 267B
-0.89%-5.83%-7.56%+7.91% 244B
-0.09%-3.58%+37.08%+52.10% 218B
-0.51%-5.36%+26.83%+92.84% 179B
Average -0.13%-3.54%+25.66%+57.33% 410.8B
Weighted average by Cap. -0.23%-3.54%+28.82%+68.86%

Financials

2026 *2027 *
Net sales 47.66B 968B 53.43B 44.4B 40.41B 76.1B 5,145B 76.66B 537B 209B 2,626B 201B 196B 8,441B 50.62B 1,028B 56.75B 47.16B 42.92B 80.83B 5,465B 81.42B 570B 222B 2,789B 213B 208B 8,966B
Net income 7.48B 152B 8.39B 6.97B 6.34B 11.95B 808B 12.04B 84.25B 32.78B 412B 31.49B 30.81B 1,325B 8.9B 181B 9.98B 8.3B 7.55B 14.22B 961B 14.32B 100B 39B 491B 37.47B 36.66B 1,577B
Net Debt 11.91B 242B 13.35B 11.09B 10.1B 19.01B 1,286B 19.15B 134B 52.16B 656B 50.11B 49.03B 2,109B 8.61B 175B 9.65B 8.02B 7.3B 13.75B 930B 13.85B 96.96B 37.72B 475B 36.24B 35.46B 1,525B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
70.81EUR
Average target price
94.06EUR
Spread / Average Target
+32.83%

Quarterly revenue - Rate of surprise